A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
About the study
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..
- Adequate Bone Marrow Function.
- Adequate Renal & Liver Function.
- Adequate Performance Status
EXCLUSION CRITERIA
Exclusion Criteria:
- Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.
- Previous high-dose chemotherapy requiring allogenic stem cell rescue.
- Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Metastatic Cancer,Solid Tumor,Advanced Cancer,NonHodgkin Lymphoma
Age (in years)
18+
Phase
Phase 1
Participants needed
174
Est. Completion Date
Feb 1, 2024
Treatment type
Interventional
Sponsor
ALX Oncology Inc.
ClinicalTrials.gov identifier
NCT03013218
Study number
AT148001
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?